Market Performance Overview
Revelation Biosciences (ticker: REVB) experienced a decline of 3.18 % in the 24‑hour period ending at 09:11 PM Central Europe on Tuesday, 20 October 2026. At the close of trading, the share price stood at USD 3.45 on major exchanges. With a floating supply of approximately 4 million shares, the company’s current market capitalization is USD 1.9 million. In the last 24 hours, roughly USD 142.9 k of shares were exchanged.
Over the past month, the share price has fallen by 51.93 %, reflecting significant volatility in the biopharmaceutical sector. The 200‑day simple moving average remains well above the current level, at USD 9.11, underscoring the recent downward pressure. Historically, the most recent 52‑week high reached USD 40.60 on 23 January 2026, while the low of the same period was USD 3.08 on 19 October 2026.
Comparative Performance of Related Stocks
In the same 24‑hour window, the following peer companies showed varied movements:
| Company | Ticker | % Change | Current Price | Market Capitalization |
|---|---|---|---|---|
| Adagio Medical | ADGM | +21.21 % | USD 0.12 | USD 2.2 million |
| Boxlight | BOXL | +5.08 % | USD 2.90 | USD 2.2 million |
| Reliance Global | EZRA | ‑2.63 % | USD 2.41 | USD 2.3 million |
| Geovax Labs | GOVX | ‑4.20 % | USD 0.23 | USD 2.2 million |
| Focus Universal | FCUV | +0.28 % | USD 3.48 | USD 2.3 million |
While some peers have rallied, Revelation Biosciences’ decline highlights sector‑specific challenges and the broader market sentiment toward clinical‑stage biopharmaceuticals.
Company Context
Revelation Biosciences Inc., headquartered in San Diego, is a clinical‑stage biopharmaceutical enterprise focused on developing therapeutics and diagnostics for viral infections. The company leverages the innate immune system’s potential to create next‑generation solutions for viral diseases. With a global footprint, it serves customers worldwide and maintains an online presence through its Nasdaq‑listed website at www.revbiosciences.com .
The company’s recent market performance, coupled with its ambitious therapeutic pipeline, suggests that investors should monitor both the clinical development milestones and the evolving regulatory landscape that may influence future valuation.
